Upstream Bio, Inc. (NASDAQ:UPB) Stock Has Consensus Target Price of $29.67

Upstream Bio, Inc. (NASDAQ:UPB) has been given a consensus rating of “Hold” by the seven research firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $29.67.

UPB has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $36.00 price target on shares of Upstream Bio in a research note on Wednesday, September 2nd. Wall Street Zen downgraded shares of Upstream Bio from a “sell” rating to a “strong sell” rating in a report on Saturday, August 15th. JPMorgan Chase & Co. raised their price objective on Upstream Bio from $8.00 to $9.00 and gave the company a “neutral” rating in a research report on Friday, August 14th. Weiss Ratings upgraded Upstream Bio from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, August 17th. Finally, Truist Financial reduced their target price on Upstream Bio to $25.00 and set a “buy” rating on the stock in a report on Tuesday, August 11th.

Hedge Funds Weigh In On Upstream Bio

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Walleye Capital LLC bought a new stake in Upstream Bio in the 2nd quarter worth approximately $3,450,000. BlackRock Inc. purchased a new stake in shares of Upstream Bio during the 2nd quarter worth approximately $25,973,000. Deutsche Bank AG bought a new position in shares of Upstream Bio during the 2nd quarter valued at approximately $1,671,000. Squarepoint Ops LLC boosted its position in shares of Upstream Bio by 551.9% during the 2nd quarter. Squarepoint Ops LLC now owns 290,904 shares of the company’s stock valued at $2,013,000 after acquiring an additional 246,278 shares during the last quarter. Finally, Bank of America Corp DE purchased a new position in shares of Upstream Bio in the second quarter valued at $2,711,000.

Upstream Bio Stock Performance

UPB stock opened at $3.55 on Wednesday. Upstream Bio has a one year low of $3.52 and a one year high of $33.68. The company’s fifty day moving average price is $5.96 and its 200-day moving average price is $7.29. The company has a market capitalization of $194.43 million, a PE ratio of -1.22 and a beta of 1.38.

Upstream Bio (NASDAQ:UPB) last issued its earnings results on Tuesday, August 11th. The company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.01. The firm had revenue of $0.77 million during the quarter, compared to analyst estimates of $0.56 million. Upstream Bio had a negative net margin of 4,955.67% and a negative return on equity of 48.40%. On average, research analysts predict that Upstream Bio will post -2.84 EPS for the current fiscal year.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on developing therapies for inflammatory diseases. The company’s research is centered on targeting biological pathways involved in immune-system activation and chronic inflammation, with an emphasis on conditions affecting the airways.

Upstream Bio’s lead product candidate is verekitug, formerly known as UPB-101. Verekitug is a long-acting monoclonal antibody designed to selectively inhibit thymic stromal lymphopoietin, or TSLP, a cytokine that contributes to the development and persistence of inflammation.